Adenoviridae, Adeno-like Virus, Or Parvoviridae (e.g., Adenovirus, Canine Parvovirus, Mink Enteritis Virus, Hemorrhagic Enteritis Virus, Feline Panleukopenia Virus, Egg Drop Syndrome Virus, Etc.) Patents (Class 424/233.1)
-
Publication number: 20120039939Abstract: The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus.Type: ApplicationFiled: April 10, 2009Publication date: February 16, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Joseph Shiloach, Michael Betenbaugh, Pratik Jaluria, Chia Chu
-
Patent number: 8105610Abstract: The invention relates to nucleic sequences derived from a human erythrovirus type V9, fragments of the sequences and their methods of use including applications as a diagnostic reagent and as immunogenic agent.Type: GrantFiled: October 5, 2007Date of Patent: January 31, 2012Assignee: Assistance Publique Hospitaux de ParisInventors: Quang Tri Nguyen, Antoine Garbarg-Chenon, VĂ©ronique Auguste
-
Publication number: 20120003277Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Tarek Hamouda, Susan M. Ciotti
-
Publication number: 20110311536Abstract: The invention involves methods and products for inducing Treg cells for immune suppression in connection with autoimmune disease and transplant rejection.Type: ApplicationFiled: June 10, 2011Publication date: December 22, 2011Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Harald von Boehmer, Carolin Daniel
-
Patent number: 8080240Abstract: According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursers, while leaving healthy cells intact. The invention thus comprises a method of killing cancer and other neoplastic and preneoplastic cells by administration of AAV2 virus, viral particles, products or replication incompetent vectors derived there from to said cells, and pharmaceutical compositions comprising the same.Type: GrantFiled: October 21, 2005Date of Patent: December 20, 2011Assignee: The Penn State Research FoundationInventors: Craig M. Meyers, Samina Alam
-
Publication number: 20110293723Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
-
Patent number: 8067014Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.Type: GrantFiled: August 10, 2009Date of Patent: November 29, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark Kay, Dirk Grimm
-
Publication number: 20110287089Abstract: The present invention relates to the use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction and an antigen for the preparation of a pharmaceutical composition intended to orient the immune response toward a Th1 type response directed against said antigen, more particularly for the prevention and/or the treatment of cancer, infectious disease and allergy. Adjuvant compositions with synergic effect, vaccine compositions with synergic effect, and kits of part are also provided. Methods of treatment of individuals thereof are also provided.Type: ApplicationFiled: January 8, 2010Publication date: November 24, 2011Inventor: Karola Rittner
-
Patent number: 8058251Abstract: The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject.Type: GrantFiled: October 31, 2007Date of Patent: November 15, 2011Inventor: William F. Kaemmerer
-
Publication number: 20110268762Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes encoding avian influenza virus. The invention also provides methods and apparatus for use in such administration.Type: ApplicationFiled: March 25, 2011Publication date: November 3, 2011Inventors: Haroldo Toro, De-Chu C. Tang, Kent R. Van Kampen
-
Publication number: 20110256166Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.Type: ApplicationFiled: May 31, 2011Publication date: October 20, 2011Inventors: Menzo Jans Emco Havenga, Ronald Vogels, Jerald C. Sadoff, David Hone, Yasir Abdul Wahid Skeiky, Katarina Radosevic
-
Publication number: 20110243988Abstract: This invention provides compositions and methods for stabilizing a live attenuated virus in dried formulations. In particular, compositions and methods of preparing a dried vaccine are provided that stabilize the viability of live vaccines such as measles and adenovirus at room temperature.Type: ApplicationFiled: October 1, 2010Publication date: October 6, 2011Inventors: Satoshi Ohtake, Vu Truong-Le, Luisa Yee, Russell A. Martin, David Lechuga-Ballesteros
-
Publication number: 20110236419Abstract: The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.Type: ApplicationFiled: February 25, 2011Publication date: September 29, 2011Inventors: Jean-Christophe Audonnet, Jules Minke
-
Patent number: 8017130Abstract: The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form.Type: GrantFiled: November 5, 2009Date of Patent: September 13, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Gary J. Nabel, Nancy J. Sullivan, Thomas W. Geisbert, Peter B. Jahrling
-
Publication number: 20110217332Abstract: The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer.Type: ApplicationFiled: January 18, 2005Publication date: September 8, 2011Inventors: Stefano Colloca, Alfredo Nicosia, Elisabetta Sporeno, Paolo Palazzolo, Agostino Cirillo, Bruno Bruni Ercole, Annalisa Meola
-
Patent number: 8012467Abstract: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.Type: GrantFiled: November 15, 2005Date of Patent: September 6, 2011Assignees: Crucell Holland B.V., Aeras Global TB Vaccine FoundationInventors: Menzo J. E. Havenga, Ronald Vogels, Jerald Sadoff, David Hone, Yasir A. W. Skeiky, Katarina Radosevic
-
Publication number: 20110212123Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.Type: ApplicationFiled: February 22, 2011Publication date: September 1, 2011Inventors: Haixiang Lin, Lie Tao Victor Li
-
Publication number: 20110189235Abstract: A vaccine composition may be administered to a subject to increase immunity to an adipogenic adenovirus-related cancer. The vaccine composition stimulates the production of adipogenic adenovirus neutralizing antibodies in the subject, which may increase immunity to the adipogenic adenovirus-related cancer in the subject.Type: ApplicationFiled: February 7, 2011Publication date: August 4, 2011Applicant: OBETECH, LLCInventor: Richard L. Atkinson
-
Publication number: 20110189234Abstract: The present invention is concerned with means and methods for producing adenovirus particles comprising a chimeric adenovirus spike protein that essentially lacks a functional knob domain. One aspect of the invention is concerned with a method for producing adenovirus particles comprising providing cells that are permissive for adenovirus replication with an adenovirus vector, with nucleic acid encoding said chimeric adenovirus spike protein and with nucleic acid encoding at least one adenovirus E3 region protein or a functional part, derivative and/or analogue thereof, said method further comprising culturing said permissive cells to allow for at least one replication cycle of said adenovirus virus and harvesting said adenovirus particle.Type: ApplicationFiled: February 13, 2007Publication date: August 4, 2011Inventors: Victor Willem Van Beusechem, Frederik Hubertus Emanuel Schagen
-
Publication number: 20110171262Abstract: Parvoviral capsid with incorporated Gly-Ala repeat region The present invention provides a nucleic acid construct comprising a nucleic acid sequence encoding a parvoviral VP1, VP2 and VP3 capsid proteins comprising an immuno evasion repeat sequence. In addition, the present invention provides a cell comprising such construct, a parvoviral virion comprising a capsid protein that comprises an immune evasion repeat sequence, use of that parvoviral virion in gene therapy and a pharmaceutical composition comprising such parvoviral virion.Type: ApplicationFiled: June 17, 2009Publication date: July 14, 2011Inventors: Andrew Christian Bakker, Valerie Sier-Ferreira, Sebastiaan Menno Bosma
-
Publication number: 20110165224Abstract: A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny.Type: ApplicationFiled: December 15, 2010Publication date: July 7, 2011Applicants: UNIVERSITY OF SASKATCHEWAN, UNIVERSITY OF GUELPHInventors: Susantha Gomis, Suresh Tikoo, Davor Ojkic
-
Patent number: 7968340Abstract: The present invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one modification which brings about a reduction in the antigenicity, its production and use.Type: GrantFiled: June 15, 2009Date of Patent: June 28, 2011Assignee: MediGene AGInventors: Michael Hallek, Anne Girod, Martin Ried
-
Publication number: 20110150940Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.Type: ApplicationFiled: December 16, 2010Publication date: June 23, 2011Applicant: Universiteit GentInventors: Jean Paul Remon, Chris Vervaet, Evy Corbanie, Johannes Hubertus Henricus van Eck, Wilhelmus Johannes Mathernus Landman
-
Publication number: 20110150930Abstract: Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Codon-optimized circumsporozoite genes are disclosed. Replication-defective adenoviruses may be used, derived from serotypes that encounter low titers of neutralizing antibodies. Also described is the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: ApplicationFiled: December 1, 2010Publication date: June 23, 2011Applicant: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Publication number: 20110135688Abstract: This invention relates to methods of increasing titer of recombinant PAdV-3 produced in porcine host cells by increasing PAdV-3 encapsidation efficiency and compositions comprising the same. More particularly, the invention describes optimized recombinant PAdV-3 vectors in which the packaging signal has been optimized. In particular, the optimization involves increasing the number of packaging elements in the PAdV-3 viral genome.Type: ApplicationFiled: November 30, 2010Publication date: June 9, 2011Inventor: Michael Sheppard
-
Publication number: 20110123569Abstract: The invention is directed to a live attenuated serotype 14 adenovirus, and a method of inducing an immune response against a serotype 14 adenovirus in a mammal using the live attenuated serotype 14 adenovirus.Type: ApplicationFiled: December 11, 2008Publication date: May 26, 2011Applicants: GenVec, Inc., The Government of the United States of America, as represented by the SecretaryInventors: Jason G.D. Gall, Christoph Kahl, Gary J. Nabel
-
Patent number: 7947288Abstract: The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.Type: GrantFiled: April 27, 2009Date of Patent: May 24, 2011Assignee: Transgene S.A.Inventor: Stephane Paul
-
Publication number: 20110091502Abstract: Provided herein are sequences of the genomes and encoded proteins of a new human parvovirus, Humink parvovirus, and variants thereof. Also provided are methods of detecting the Humink parvovirus and diagnosing Humink parvovirus infection, methods of treating or preventing Humink parvovirus infection, and methods for identifying anti-Humink parvovirus compounds.Type: ApplicationFiled: October 15, 2010Publication date: April 21, 2011Applicant: BLOOD SYSTEMS, INC.Inventors: ERIC DELWART, AMIT KAPOOR
-
Publication number: 20110091496Abstract: The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The methods are useful in preventing or treating a subject having a disease or an infection. In particular examples, the methods are useful for preventing or treating a viral infection.Type: ApplicationFiled: January 21, 2009Publication date: April 21, 2011Inventors: Barney S. Graham, Christopher B. Buck, Jeffrey N. Roberts, Teresa R. Johnson, John Nicewonger, Rhonda Kines, John T. Schiller
-
Publication number: 20110086063Abstract: The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody directed against the addictive drug. The invention further provides a method of inducing an immune response against an addictive drug or reducing the effect of an addictive drug in a human by ad-ministering to the human the aforementioned adenovirus-antigen conjugate or antibody encoding adenoviral vector.Type: ApplicationFiled: June 4, 2009Publication date: April 14, 2011Applicant: CORNELL UNIVERSITYInventors: Ronald G. Crystal, Philip L. Leopold, Stefan Worgall, Julie L. Boyer
-
Patent number: 7923436Abstract: The invention uses recombinant parvoviruses, and particularly recombinant adeno-associated virus (rAAV) to deliver genes and DNA sequences for gene therapy following manipulation of the therapeutic virus for packaging and transport. The invention delivers therapeutic viral vectors via rAAV affixed to support matrixes (i.e., sutures, surgically implantable materials, grafts, and the like).Type: GrantFiled: April 5, 2007Date of Patent: April 12, 2011Assignee: University of North Carolina - Chapel HillInventors: Paul E. Monahan, Richard Jude Samulski, Joseph E. Rabinowitz
-
Publication number: 20110081377Abstract: The present invention generally features methods for the mucosal delivery of immunogenic compositions and methods for treating or preventing diseases featuring such immunogenic compositions. In particular embodiments, the immunogenic compositions are genetic vaccines formulated as aerosols.Type: ApplicationFiled: September 21, 2010Publication date: April 7, 2011Applicant: The United States, as represented by the Secretary Department of Health and Human ServicesInventors: Mario Roederer, Srinivas Rao, Gary J. Nabel, Charla A. Andrews
-
Publication number: 20110064768Abstract: An immunogenic composition comprising a viral vector, said vector comprising a nucleic acid sequence encoding a C4bp domain or variant or fragment thereof and a nucleic acid sequence encoding an antigen of interest.Type: ApplicationFiled: April 10, 2008Publication date: March 17, 2011Inventors: Simon Draper, Adrian Hill, Fergal Hill
-
Patent number: 7906111Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.Type: GrantFiled: September 30, 2004Date of Patent: March 15, 2011Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
-
Publication number: 20110059135Abstract: This invention pertains to tropism-modified adenoviral vectors optimized for antigen delivery that induced both humoral and cellular immune responses, as well as a method of constructing and using such vectors. The vectors of the present invention may incorporate an epitope or an antigen into a capsid protein. Methods for treating of a host with an effective amount of adenovirus vector of the present invention are also provided.Type: ApplicationFiled: September 3, 2010Publication date: March 10, 2011Inventors: IMRE KOVESDI, SUSAN J. HEDLEY
-
Publication number: 20110002961Abstract: A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain antigens for identification and which cells are capable of presenting at least part of said antigen on their surface by an HLA class I (or equivalent) molecule, the method comprising administering to the patient a therapeutically effective amount of either antigen presenting cells which have been gene delivered with the interleukin 12 (IL-12) gene plus a relevant antigen. In a related set of claims said method refers to the administration to a patient of therapeutic levels of cytotoxic T lymphocytes (CTL) which recognize at least part of said antigen when presented by an HLA class I (or equivalent) molecule on the surface of a cell and which these CTL were stimulated by the antigen presenting cells, mentioned in the first section, which have been gene delivered with the interleukin 12 (IL-12) gene plus a relevant antigen.Type: ApplicationFiled: March 3, 2009Publication date: January 6, 2011Inventor: Paul Hermonat Hermonat
-
Publication number: 20100322896Abstract: This invention relates to the use of a molecular adjuvant to generate an immune response in a host. In particular, the molecular adjuvant may be a TLR signalling pathway component, a co-stimulatory molecule, an NKG2D ligand, IL- or IL-15.Type: ApplicationFiled: October 7, 2008Publication date: December 23, 2010Inventors: Adrian Vivian Sinton Hill, David Wyllie, Karen Colbjorn Larsen, Alexandra Jane Spencer, Matthew Cottingham, Sarah Gilbert
-
Patent number: 7851196Abstract: The present invention provides methods of purifying encapsidated virus, e.g., viral particles comprising viral nucleic acid, from compositions comprising encapsidated viral nucleic acid and viral particles that lack viral nucleic acid; methods for reducing the particle:genome ratio in a preparation of encapsidated viral nucleic acid; and methods for selectively inactivating viral particles that lack viral nucleic acid in a liquid composition comprising encapsidated viral nucleic acid and the viral particles that lack viral nucleic acid. The methods generally involve subjecting the composition to hydrostatic pressure such that the viral particles lacking viral nucleic acid are selectively inactivated.Type: GrantFiled: April 24, 2007Date of Patent: December 14, 2010Assignee: The Regents of the University of CaliforniaInventors: David V. Schaffer, Joshua N. Leonard
-
Publication number: 20100310602Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.Type: ApplicationFiled: June 4, 2010Publication date: December 9, 2010Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20100303859Abstract: Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production.Type: ApplicationFiled: May 22, 2008Publication date: December 2, 2010Applicant: NATURE TECHNOLOGY CORPORATIONInventor: James A. Williams
-
Publication number: 20100297177Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.Type: ApplicationFiled: June 2, 2008Publication date: November 25, 2010Applicants: Ludwig-Maximillians-Universitaet, Klinikum der Universitaet zu KoelnInventors: Hildegard Buening, John Nieland, Luca Perabo, Daniela Kuehn, Kerstin Lux, Michael Hallek, Markus Hoerer, Mirko Ritter
-
Publication number: 20100272753Abstract: Recombinant adenovirus vaccines comprising recombinant adenoviruses whose hexon, fiber or protein IX capsid proteins are engineered to include exogenous peptide segments, e.g. vaccines for human papillomavirus (HPV) and malaria.Type: ApplicationFiled: October 26, 2007Publication date: October 28, 2010Applicant: The Johns Hopkins UniversityInventors: Gary W. Ketner, Richard B. Roden, Fidel P. Zavala
-
Patent number: 7820441Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: GrantFiled: September 21, 2001Date of Patent: October 26, 2010Assignee: The Regents of the University of MichiganInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Publication number: 20100260800Abstract: The invention relates to Adeno-associated virus vectors. In particular, it relates to Adeno-associated virus vectors with modified capsid proteins and materials and methods for their preparation and use.Type: ApplicationFiled: June 21, 2010Publication date: October 14, 2010Applicant: Nationwide Children's Hospital Inc.Inventors: Jeffrey S. Bartlett, Matthew Stachler
-
Publication number: 20100260799Abstract: A recombinant vector comprises simian adenovirus SAdV-31 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-31 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.Type: ApplicationFiled: November 24, 2008Publication date: October 14, 2010Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Soumitra Roy, James M. Wilson, Luc H. Vandenberghe
-
Publication number: 20100247621Abstract: The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.Type: ApplicationFiled: November 30, 2007Publication date: September 30, 2010Applicant: Government of the US, as represented by the Secretary, Department of Health and Human ServicesInventors: Barney S. Graham, Teresa R. Johnson
-
Patent number: 7803365Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.Type: GrantFiled: March 13, 2007Date of Patent: September 28, 2010Assignee: Biovec, LLCInventors: Lakshman R. Sehgal, Jonathan Wong
-
Patent number: 7799329Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.Type: GrantFiled: May 30, 2007Date of Patent: September 21, 2010Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Patent number: 7785602Abstract: This invention relates to a recombinant vector including a recombinant porcine adenovirus, stably incorporating and capable of expression of at least one heterologous nucleotide sequence. The nucleotide sequence is preferably one which encodes an antigenic determinant of Hog Cholera Virus or Pseudorabies virus. The further invention relates to a method of production of recombinant vectors, to methods of preparation of vaccines based on the vectors, to administration strategies and to methods of protecting pigs from disease.Type: GrantFiled: August 22, 2008Date of Patent: August 31, 2010Assignee: Vectogen Pty Ltd.Inventors: Michael A. Johnson, Jeffrey Michael Hammond, Richard J. McCoy, Michael G. Sheppard
-
Patent number: 7785886Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).Type: GrantFiled: April 28, 2004Date of Patent: August 31, 2010Assignees: Xenon Pharmaceuticals, Inc., Univ. of British ColumbiaInventors: Michael R. Hayden, Angela R. Brooks-Wilson, Simon N. Pimstone